HC Wainwright & Co. Reiterates Buy on Janux Therapeutics, Maintains $35 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Swayampakula Ramakanth has reiterated a Buy rating on Janux Therapeutics (NASDAQ:JANX) and maintained a $35 price target for the company's stock.
November 13, 2023 | 3:44 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst reaffirms a Buy rating on Janux Therapeutics with a $35 price target, indicating a positive outlook for the stock.
The reiteration of a Buy rating and maintenance of a $35 price target by a reputable analyst can instill confidence in investors and potentially lead to a positive short term impact on the stock price of Janux Therapeutics.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100